SpazcosoftApr 8, 2024
Christos Argyropoulos MD PhD
If one wants to play the #vaxx game against #covid19, then one must give 3 (updated) shots per year, i.e. release the #gigavaxx. While this has been obvious since mid 2021, this report provides numbers showing that the #gigavaxx is still valid in the Omicron era
https://www.ecdc.europa.eu/en/publications-data/interim-analysis-covid-19-vaccine-effectiveness-against-hospitalisation-due-covid
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation due to COVID-19 and death using electronic health records in eight European countries: first update

This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.

European Centre for Disease Prevention and Control
Apr 8, 2024 at 12:09pmTusky
Show threadJ.H.NoyesApr 9, 2024

@ChristosArgyrop

Psst:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312960/

I could be wrong, but I suspect those are way less common in vaccinees along the 120 day interval. The 90/120 decline coincides with the decline of vax induced Short Term Germinal Centers.

@graydon

IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition

The glycosylation of IgG plays a critical role during human SARS-CoV-2, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during acute viral infection in humans. In vitro evidence suggests ...

PubMed Central (PMC)